Kindeva Drug Delivery has acquired Summit Biosciences Inc., an intranasal drug-delivery CDMO, adding a new drug-delivery platform and further expanding Kindeva’s capabilities across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).
 
Summit’s 55,000-sq.-ft. cGMP facility in Lexington, KY adds to Kindeva’s global manufacturing footprint of nine development and manufacturing facilities across the U.S. and U.K. The facility is approved by the U.S. FDA and EMA and features specialized labs and integrated manufacturing operations for intranasal medicines.

“Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting,” said Kindeva CEO Milton Boyer. “Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally.”
 
Departing Summit Chairman and CEO Richard D. Cohen added, “Joining Kindeva strengthens our ability to deliver best-in-class nasal product development and manufacturing. Under Kindeva’s leadership, our dedicated and talented workforce will further drive our founder’s vision of increasing the availability of nasal drug-delivery options.”